ストックスクリーナーアプリを入手
3.1584
7.20%
-0.245
前日終値:
$3.4034
開ける：
$3.17
24時間の取引高:
28,706
Relative Volume:
2.18
時価総額：
$26.98M
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
-23.15%
1か月 パフォーマンス:
-52.69%
6か月 パフォーマンス:
-62.97%
1年 パフォーマンス:
-58.50%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$2.62
$4.46
52週間の値動き範囲:
$2.62
$10.47
Impact BioMedical, Inc. Stock (IBO) Company Profile
Compare IBO vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBO
Impact BioMedical, Inc.
|
3.1584 | 26.98M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Impact BioMedical, Inc. (IBO) 最新ニュース
Stock splits calendar for: - Yahoo Finance Australia
Form 4 Impact Biomedical Inc For: 24 September By Investing.com - Investing.com India
10% Owner Inc. Dss, Sells 906 Shares of Impact BioMedical Inc (I - GuruFocus
Form 4 Impact Biomedical Inc For: 24 September By Investing.com - Investing.com Canada
DSS Inc., 10% owner, sells $1,686 in Impact Biomedical stock By Investing.com - Investing.com South Africa
DSS Inc., 10% owner, sells $1,686 in Impact Biomedical stock - Investing.com
DSS Inc., 10% owner, sells $1,686 in Impact Biomedical stock By Investing.com - Investing.com India
DSS Inc., 10% owner, sells $1,686 in Impact Biomedical stock By Investing.com - Investing.com Canada
DSS Inc., 10% owner, sells $1,686 in Impact Biomedical stock By Investing.com - Investing.com UK
Across three days, DSS sold 906 Impact Biomedical (IBO) shares at prices from $0.55 to $7.0587. - Stock Titan
Impact Biomedical executes 1-for-12.62 reverse stock split ahead of Zoar Ltd. merger - Pluang
Impact BioMedical (IBO) moves toward Zoar merger vote - Stock Titan
DSS Says Zoar Files Form F-4 for Impact Biomedical Combination - citybiz.co
Impact Biomedical files F-4 for business combination - Investing.com
Impact Biomedical Inc. Announces Filing of F-4 Registration Statement for Proposed Business Combination with Zoar Limited - Quiver Quantitative
DSS Announces Filing of Form F-4 by Zoar Limited in Connection with Proposed Business Combination with Impact Biomedical - Quiver Quantitative
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited - Yahoo Finance
Impact Biomedical Inc Announces Filing of Form F-4 - GlobeNewswire
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited) - Yahoo Finance
Impact Biomedical files F-4 for business combination By Investing.com - Investing.com UK
Impact Biomedical's proposed merger could create a company developing and supplying drug ingredients - Stock Titan
A proposed deal involving Impact Biomedical reaches U.S. regulators. It is not approved yet. - Stock Titan
IBO: Impact BioMedical Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Impact Biomedical approves 1-for-12.62 reverse stock split ahead of proposed Zoar merger - TradingView
Impact BioMedical (NYSE: IBO) shrinks share count ahead of proposed Zoar merger - Stock Titan
Impact Biomedical expects shares to fall from about 107.8 million to 8.54 million - Stock Titan
Impact Biomedical corrects merger exchange ratio, sets reverse stock split - Investing.com
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 - GlobeNewswire
Impact Biomedical Announces 1-for-12.62 Reverse Stock Split Ahead of Proposed Zoar Limited Merger - Moomoo
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) - Yahoo Finance
Impact BioMedical approves 1-for-12.62 reverse stock split - Investing.com
Impact BioMedical Announces 1-for-12.62 Reverse Stock Split Ahead of Proposed Zoar Merger - Quiver Quantitative
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for - GlobeNewswire
About 108 million shares are expected to become 8.5 million as Impact BioMedical pursues a proposed merger. - Stock Titan
Impact BioMedical to Effect 1-for-12.62 Reverse Stock Split - marketscreener.com
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.) - Yahoo Finance
Impact BioMedical, Inc. (IBO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
IBO - Finviz
Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO - Business Wire
Impact BioMedical Inc. Reports Going Concern Audit Opinion - GlobeNewswire
Impact BioMedical Inc. Reports "Going Concern" Qualification in Annual 10-K Audit Opinion and Plans Merger with Dr. Ashley's Ltd. - Quiver Quantitative
Impact Biomedical (IBO) 10K Form and Latest SEC Filings 2026 - MarketBeat
Grady Jason sells Impact Biomedical (IBO) stock worth $32,505 - Investing.com
Impact BioMedical Advances Dr Ashleys Combination With Amended Terms, Holder Support and DSS Funding - TradingView
Impact BioMedical, Inc. (IBO) 財務データ
Impact BioMedical, Inc. (IBO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Impact BioMedical, Inc. (IBO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Macko Todd D | Chief Financial Officer |
Mar 27 '26 |
Sale |
0.56 |
43,400 |
24,369 |
155,122 |
| Macko Todd D | Chief Financial Officer |
Mar 25 '26 |
Sale |
0.60 |
1,600 |
961 |
198,122 |
| Grady Jason | Director |
Mar 23 '26 |
Sale |
0.65 |
50,000 |
32,505 |
250,182 |
1.35%
大文字化:
|
ボリューム (24 時間):